Shanghai Pharma wins approval for myasthenia gravis drug, sets Q3 briefing

Shanghai Pharmaceuticals Holding Co., Ltd. announced that its subsidiary, Shanghai No. 1 Pharmaceutical Co., Ltd., has received approval for the production of pyridostigmine bromide sustained-release tablets from the National Medical Products Administration. This drug, used for myasthenia gravis, was originally launched in the US in 1959. Shanghai No. 1 Pharmaceutical filed for approval in March 2024, investing approximately RMB 1,600.9 million in R&D. No other domestic companies currently list pyridostigmine bromide sustained-release tablets, and 2024 hospital procurement in mainland China was RMB 6,029 million.

The approval is expected to enhance Shanghai Pharmaceuticals' market share and competitiveness. The company will also hold a 2025 third-quarter performance briefing on Wednesday, November 5, 2025, from 10:00 to 11:00 AM. The online briefing will discuss third-quarter operating results and financial status, addressing investor questions.

Investors can submit questions from October 29 to November 4, 2025. Key attendees will include executive director and president Shen Bo, independent director Gu Chaoyang, vice president and CFO Zhou Yatong, and vice president and board secretary Zhong Tao.